Teva launches generic Lunesta in the U.S.
JERUSALEM — Teva Pharmaceutical Industries announced the launch of a generic equivalent to Lunesta (eszopiclone tablets) in 1-,2- and 3-mg form in the United States. The drug is used to treat insomnia.
Lunesta tablets, which are marketed by Sunovion Pharmaceuticals, had annual sales of $852 million in the United States as of December 2013, according to IMS data.
IMS: Spending on medicines up slightly on greater utilization of healthcare system
PARSIPPANY, N.J. — Total spending on U.S. medicines increased 1% on a real per capita basis in 2013, while the use of healthcare services overall rose for the first time in three years, according to a new report issued today by the IMS Institute for Healthcare Informatics.
The study, "Medicine Use and Shifting Costs of Healthcare: A Review of the Use of Medicines in the United States in 2013," found that total dollars spent on medications in the United States reached $329.2 billion last year, up 3.2% on a nominal basis and a rebound from the 1% decline in 2012. Primary drivers include the reduced impact of patent expiries, price increases, higher spending on innovative new medicines and greater use by patients of the healthcare system.
Patent expiries in 2013 contributed $19 billion to lower medicine spending, compared with $29 billion the previous year. At the same time, 36 New Molecular Entities launched in 2013, the largest number in a decade, focused on specific disease areas that include oncology, hepatitis C and HIV. Overall utilization of healthcare services grew slightly as consumers returned to the healthcare system — primarily through more office visits to specialist physicians as well as outpatient treatments — following several years of self-rationing.
In addition, patients with insurance paid higher out-of-pocket expenses in the form of deductibles and co-insurance last year, even as prescription co-payments declined and are now less than $5 for more than half of all prescriptions filled.
“Following several years of decline, 2013 was striking for the increased use by patients of all parts of the U.S. healthcare system — even in advance of full implementation of the Affordable Care Act,” said Murray Aitken, executive director of the IMS Institute for Healthcare Informatics. “Growth in medicine spending remains at historically low levels despite a significant uptick last year, and continues to contribute to the bending of the healthcare cost curve.”
The report’s key findings include:
- Increase in the utilization of healthcare services and medicines. The number of physician office visits, hospitalizations and prescriptions filled all increased in 2013. The number of patient office visits to primary care physicians fell by 0.7% in 2013, while visits to specialists increased by 4.9% overall and by 9.5% for seniors. The number of hospitals visits increased last year, most notably by patients who were commercially insured and received outpatient treatments. Patients filled an average of more than 12 retail prescriptions last year, up nearly 2% year over year. Those aged 65 and over filled an average of 28 prescriptions annually, down slightly from 2012;
- Spending on medicines. While drug spending levels have contributed to slower growth in healthcare costs since 2007, nominal spending rose sharply last year. The largest single driver of the 4.2 percentage point shift in spending growth in 2013 was the $10 billion lower impact of patent expiries. Price increases for branded products added $4 billion more in spending growth last year compared to 2012; however, net price growth was essentially flat year over year, reflecting off-invoice discounts and rebates. Overall spending on medicines remained concentrated in traditional small-molecule pills dispensed through retail pharmacies, even as higher growth was seen in biologics and specialty drugs – particularly in retail and mail-order settings;
- Transformations in disease treatment. Patients gained access to 36 New Molecular Entities in 2013, including 10 new notable cancer treatments — the most in more than a decade. A total of 27 new oncology drugs have launched in the past three years. Additionally, clusters of innovation are transforming patient care in hepatitis C, multiple sclerosis and diabetes, as well as stroke and acute coronary syndrome. In addition to improved patient outcomes, these and other transformational treatments bring with them a shift in where costs are being incurred in the healthcare system — yielding the promise of fewer doctor office visits, less hospitalizations and reduced use of long-term care facilities. Seventeen orphan drugs — developed for patient populations of fewer than 200,000 individuals — launched in 2013, the most in any year since the passage of the Orphan Drug Act in 1983. The next decade promises a much faster approval process for drugs gaining the Food and Drug Administration’s new Breakthrough Therapy Designation, IMS noted; and
- Patient payment for healthcare and medicines. Patients with insurance are incurring higher out-of-pocket costs for healthcare services despite lower co-pays for many prescriptions and additional discounts for preventive medicines. Prescription drug costs paid by most patients are declining, with average out-of-pocket costs falling below $5 for 57% of all retail prescriptions filled. At the same time, 30% of total patient out-of-pocket costs relate to just 2.3% of prescriptions, often high-cost specialty medicines. As many as 23% of prescriptions now carry no out-of-pocket costs, a dramatic rise in 2013 driven by common preventive medicines that include oral contraceptives.
The full version of the report, including a detailed description of the methodology, can be downloaded as an app via iTunes at itunes.apple.com/app/ims-institute/id625347542.
The study was produced independently as a public service, without industry or government funding.
Tanzeum granted FDA approval
SILVER SPRING, Md. — The Food and Drug Administration on Tuesday announced that it has approved Tanzeum (albiglutide) subcutaneous injection, which is used to improve glycemic control in adults with Type 2 diabetes.
Type 2 diabetes affects approximately 24 million people and accounts for more than 90% of diabetes cases diagnosed in the United States.
"Tanzeum is a new treatment option for the millions of Americans living with Type 2 diabetes," said Curtis Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research. “It can be used alone or added to existing treatment regimens to control blood sugar levels in the overall management of diabetes.”
Tanzeum shouldn’t be used to treat people with Type 1 diabetes; those with increased ketones in their blood or urine; or as first-line therapy for patients who can’t be managed with diet and exercise.